Professor David Adler examines how Abu Dhabi’s integrated life sciences strategy, anchored by the HELM cluster and recent collaborations with MIT and Sanford Burnham Prebys, could address a persistent translational gap. He argues that giving promising academic programmes early access to pharmaceutical-development expertise, spanning biomarkers, regulatory strategy and manufacturing, may shape key experimental decisions before discoveries approach licensing or investment.
Abu Dhabi is building a life sciences ecosystem in which research, clinical care, investment, manufacturing and commercialisation are increasingly connected.
HELM and the translational pathway
Its Health, Endurance, Longevity, and Medicine (HELM) cluster was created as an integrated platform for research, development, manufacturing and commercialisation. In July, Abu Dhabi announced two strategic collaborations with MIT spanning cancer research, translational science and clinical innovation. In August, the Department of Health – Abu Dhabi signed a memorandum of understanding with Sanford Burnham Prebys for a collaboration extending from early target identification through translational validation and preclinical development.
These initiatives already address parts of the difficult journey from scientific discovery towards clinical application. The Sanford Burnham Prebys collaboration, in particular, shows that Abu Dhabi is not treating drug discovery and translational development as separate activities.
But there is a more specific question. These partnerships connect institutions, expertise and infrastructure. Do they also ensure that a researcher working on a promising therapeutic discovery can access pharmaceutical-development judgement early enough to influence which experiments are done next?
The published initiatives do not by themselves establish that such input is available systematically across the wider academic ecosystem. Abu Dhabi could therefore build on what it is already doing by making development expertise more routinely available at the level of individual promising research programmes.
Divergent questions in discovery and development
Academic science and drug development depend on each other, but they often begin with different questions. A researcher may ask whether a biological mechanism is important and whether an experiment can demonstrate it. Someone responsible for developing a medicine must eventually ask additional questions. Which patients might benefit? How could they be identified? What evidence would justify taking an experimental therapy into patients? What scientific, clinical, regulatory or manufacturing problem could prevent the programme from succeeding? What would make the treatment meaningfully different from therapies that may exist by the time it reaches the clinic?
Those questions can become central when a discovery approaches licensing, company formation, partnering or major investment. By then, years of research may already have been built around assumptions that were never examined from a development perspective.
Embedding development judgement earlier in research
Bringing those questions forward does not mean turning universities into pharmaceutical companies. Fundamental research must remain independent and curiosity driven, and most academic discoveries will never become medicines. But once a discovery shows genuine therapeutic potential, researchers could have structured access to people who have actually developed medicines and understand clinical development, biomarkers, regulatory strategy and manufacturing.
The purpose would not be to decide whether a project is commercially attractive. It would be to identify the uncertainties that matter most before another several years of experiments are designed around it. That input might change which experiment comes next, reveal the need for a patient-selection or biomarker strategy, or expose a development problem that makes an otherwise compelling idea difficult to translate. Sometimes the most useful conclusion may be that a particular therapeutic path should not be pursued. Finding that out earlier is also progress.
I have been exploring this question in Israel through an initiative at the Hebrew University of Jerusalem and Ben-Gurion University of the Negev. Recently profiled by The Scientist and Ynetnews, it includes a graduate course bringing senior pharmaceutical and biotechnology executives into the academic environment, engagement around promising research programmes and a planned Pharma-Academic Strategic Task Force intended to create sustained interaction between researchers and industry leaders.
Whether this approach improves the translation of discoveries into medicines will have to be demonstrated. Abu Dhabi does not need to reproduce it. In several respects, the emirate is already applying the same principle through major translational partnerships. The opportunity is to extend that principle more widely.
Extending translational principles across the ecosystem
Through HELM, Abu Dhabi has already brought UAE University, NYU Abu Dhabi, the Abu Dhabi Stem Cells Centre and government health and investment organisations into a common life sciences strategy. Selected therapeutic research programmes could receive development input while important experiments are still being planned. Graduate researchers could learn not only how discoveries are made, but how development decisions are made when someone tries to turn those discoveries into medicines.
This would not replace existing initiatives. It could make the connections Abu Dhabi is already building more useful at the level where scientific decisions are actually made.
Abu Dhabi is well positioned because much of its life sciences infrastructure is being developed deliberately now. Turning scientific discovery into medicine requires excellent science, but also development judgement, and the value of that judgement depends partly on when it arrives.
Abu Dhabi is already bringing many of the right organisations together. Making development expertise available earlier across promising academic research programmes could make those connections even more consequential.
About the author
Professor David Adler is Chief Scientific & Medical Officer of the PATHORA Institute of Pathology & Tissue Medicine. He is a senior pharmaceutical leader in oncology drug development and translational medicine with more than 15 years of experience, including a decade in senior leadership at Bayer AG’s Global Oncology Clinical Development organisation. He holds academic appointments at the Hebrew University of Jerusalem, Ben-Gurion University of the Negev and the University of Bonn.
